68285-22-3

Usage

Uses

Used in Pharmaceutical Industry:
Pseudoephedrine is utilized as a decongestant for the relief of nasal congestion due to its ability to constrict blood vessels in the nasal passages, improving airflow.
Used in Illicit Drug Production:
Pseudoephedrine also serves as a precursor in the illegal production of methamphetamine, although this use is discouraged and regulated due to its potential for abuse and health risks.
Used in Research and Development:
The study of pseudoephedrine's properties and effects can contribute to the development of new medications and treatments for various conditions, particularly those related to congestion and respiratory issues.

InChI:InChI=1/C11H17N/c1-8(2)10-4-6-11(7-5-10)9(3)12/h4-9H,12H2,1-3H3/t9-/m0/s1

Upstream product

• 98571-16-5 1-(4-Isopropyl-phenyl)-ethylamine; compound with (E)-3-phenyl-acrylic acid 
• 98405-01-7 1-(4-Isopropylphenyl)-ethylamine*mandelic acid salt 
• 98571-16-5 1-(4-Isopropyl-phenyl)-ethylamine; compound with (E)-3-phenyl-acrylic acid 
• 98405-01-7 1-(4-Isopropylphenyl)-ethylamine*mandelic acid 
• 222737-11-3 [(S)-1-(4-Isopropyl-phenyl)-ethyl]-carbamic acid benzyl ester 
• 52629-44-4 4-(1-methylethyl)-benzeneacetyl chloride 
• 95976-43-5 (S)-2-(4'-isopropylphenyl) propionic acid 
• 222737-10-2 (S)-4-Isopropyl-3-[(S)-2-(4-isopropyl-phenyl)-propionyl]-oxazolidin-2-one 

Downstream Products

• 98571-19-8 (S)-1-(4-Isopropyl-phenyl)-ethylamine; compound with 2-hydroxy-succinic acid 
• 222737-09-9 Phosphoric acid mono-[4-((S)-2-acetylamino-2-{(S)-1-[(S)-1-(4-isopropyl-phenyl)-ethylcarbamoyl]-3-methyl-butylcarbamoyl}-ethyl)-phenyl] ester 
• 98571-16-5 1-(4-Isopropyl-phenyl)-ethylamine; compound with (E)-3-phenyl-acrylic acid 
• 98571-16-5 1-(4-Isopropyl-phenyl)-ethylamine; compound with (E)-3-phenyl-acrylic acid 

Relevant academic research and scientific papers

Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56(lck) SH2 domain

Src homology-2 (SH2) domains are noncatalytic motifs containing approximately 100 amino acid residues that are involved in intracellular signal transduction. The phosphotyrosine-containing tetrapeptide Ac-pYEEI binds to the SH2 domain of p56(lck) (Lck) with an affinity of 0.1 μM. Starting from Ac-pYEEI, we have designed potent antagonists of the Lck SH2 domain which are reduced in peptidic character and in which the three carboxyl groups have been eliminated. The two C-terminal amino acids (EI) have been replaced by benzylamine derivatives and the pY + 1 glutamic acid has been substituted with leucine. The best C-terminal fragment identified, (S)-1-(4-isopropylphenyl)ethylamine, binds to the Lck SH2 domain better than the C-terminal dipeptide EI. Molecular modeling suggests that the substituents at the 4-position of the phenyl ring occupy the pY + 3 lipophilic pocket in the SH2 domain originally occupied by the isoleucine side chain. This new series of phosphotyrosine-containing dipeptides binds to the Lck SH2 domain with potencies comparable to that of tetrapeptide 1.